Answers are grounded in this paper and cite their sources.
The purpose of this study was to evaluate the pharmacogenomics of response to topical ocular tumor necrosis factor α (TNFα) inhibitor licaminlimab in patients with DED.
No takes yet. Share an insight, caveat, or question.
Donnenfeld et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: